High-throughput discovery of actin-binding compounds for cardiac disorders
SLAS Discovery · 2026-11 · 44 · 100342
DOI: 10.1016/j.slasd.2026.100342 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLAS Discovery, 2026-11. Verfasst von Scout Allendorf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street, Minneapolis, MN, 55455,…. Hauptthemen laut MEDLINE: Actins, High-Throughput Screening Assays, Drug Discovery, Heart Diseases. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIAMS NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Interactions between actin and myosin generate contractile force in muscle, and their dysregulation contributes to severe myopathies. While small-molecule therapeutics targeting myosin have progressed, actin remains a largely unexplored target. We sought to identify small molecules that bind actin and differentially modulate cardiac and skeletal actomyosin interactions, with the goal of developing cardiac-specific therapeutics. We previously established a time-resolved fluorescence resonance energy transfer (TR-FRET) biosensor, consisting of fluorescently labeled actin (donor) and a 12-amino acid peptide (ANT) mimicking the myosin essential light chain N-terminus (acceptor). Following previous validation in a 384-well pilot screen, we have now miniaturized the FRET assay to a 1536-well format and screened a library of 2684 FDA-approved compounds. Multiple compounds significantly altered the actin-myosin interaction, with several showing greater effects on cardiac than skeletal muscle. Identified compounds either enhanced or inhibited actomyosin activity-effects consistent with potential therapeutic mechanisms for dilated or hypertrophic cardiomyopathy, respectively. This study establishes a robust, high-throughput, actin-targeted screening platform and identifies actin-binding small molecules with isoform-specific effects. These findings support the feasibility of developing actin-directed therapeutics for cardiac disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street, Minneapolis, MN, 55455, USA.
- Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street, Minneapolis, MN, 55455, USA. Electronic address: thaku015@umn.edu.
Förderung
- NIA NIH HHS
- NIAMS NIH HHS
- National Institute on Aging
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Allendorf, S., Carter, A. L., Thompson, A. R., Rebbeck, R. T., Thomas, D. D., & Guhathakurta, P. (2026). High-throughput discovery of actin-binding compounds for cardiac disorders. SLAS Discovery, 44, 100342. https://doi.org/10.1016/j.slasd.2026.100342
Vancouver
Allendorf S, Carter AL, Thompson AR, Rebbeck RT, Thomas DD, Guhathakurta P. High-throughput discovery of actin-binding compounds for cardiac disorders. SLAS Discovery. 2026;44:100342. doi:10.1016/j.slasd.2026.100342
BibTeX
@article{Allendorf2026,
author = {Allendorf, Scout and Carter, Anna L and Thompson, Andrew R and Rebbeck, Robyn T and Thomas, David D and Guhathakurta, Piyali},
title = {High-throughput discovery of actin-binding compounds for cardiac disorders},
journal = {SLAS Discovery},
year = {2026},
volume = {44},
pages = {100342},
doi = {10.1016/j.slasd.2026.100342}
}
EUVIMED